N
NovaGo Therapeutics
Biotech & Life Sciences · Schlieren, Switzerland · Founded 2015
Human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration MoreLess
NovaGo Therapeutics, founded in 2015 in Schlieren, Switzerland, is a development-stage biotech company specializing in human antibody therapeutics aimed at promoting blood vessel and nerve growth. The company is focused on creating innovative treatments for cerebral stroke, spinal cord injury, and diabetic retinopathy (DR), a leading cause of blindness in adults and a common complication of Type 1 and Type 2 Diabetes. NovaGo's proprietary human antibodies have the potential to become safe and effective treatments in both ophthalmology and central nervous system indications. The company's business model revolves around the research and development of these therapeutic antibodies, with plans to initiate clinical development for its lead molecule targeting diabetic retinopathy. NovaGo generates revenue through partnerships, grants, and future commercialization of its therapeutic solutions. Keywords: human antibody therapeutics, nerve repair, blood vessel growth, diabetic retinopathy, cerebral stroke, spinal cord injury, ophthalmology, central nervous system, biotech, clinical development.
Company overview
NovaGo Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Schlieren, Switzerland
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 74.2
Valuation & funding
NovaGo Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2026 | $30M | $120M | Wings for Life · Neurimmune Holding · Swiss InsurEvolution Partners Holding · Pureos Bioventures | ↗ |
| SERIES A✓Equity / VC | Mar 2019 | $9.7M | $39M | Neurimmune Holding · Pureos Bioventures | ↗ |
| SPINOUT✓Other financing | Mar 2015 | $0 | — | University of Zürich | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 10 |
| 2025 | 10 |
| 2024 | 10 |
| 2023 | 6 |
| 2022 | 5 |
| 2021 | 8 |
Growth signals
NovaGo Therapeutics website traffic
Latest recorded traffic for NovaGo Therapeutics is 720 monthly website visits, down 26.5% over the last three months. NovaGo Therapeutics's team grew 0% over the past year.
Comparisons
NovaGo Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
NovaGo Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on NovaGo Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where NovaGo Therapeutics has talent and traffic
team presence
In the news
Latest news about NovaGo Therapeutics
Recent press, funding announcements, and product moves mentioning NovaGo Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about NovaGo Therapeutics
An AI-synthesized read of the highest-engagement posts about NovaGo Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NovaGo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.